Clinical Trial: Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma (NIMBUS)

Share this article:
Clinical Trial: Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma (NIMBUS)

Sponsor and Collaborators

Celgene Corporation

Contact
Contact: Associate Director, Clinical Trial Disclosure
1-888-260-1599
clinicaltrialdisclosure@celgene.com

Principal Investigator
Study Director: Mohamed Zaki, MD, PhD Celgene Corporation

ClinicalTrials.gov Identifier
NCT01311687
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Multiple Myeloma Clinical Trials

Clinical Trial: Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple ...

Clinical trial focusing on bone marrow transplantation and rental transplant for multiple myeloma. Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

Clinical Trial: Study of ACY-1215 Alone and in Combination With Bortezomib and ...

Clinical trial focusing on ACY-1215, bortezomib, and dexamethasone. Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Clinical Trial: Prognostic Potential of Cell Surface Markers and Pim Kinases in ...

Clinical trial focusing on cell surface markers and pim kinases. Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma